SCHEMBL24791336

SCHEMBL24791336

COCc1nc(O)c2cc(Br)c(OC)cc2n1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AXL P30530 1/20 0.37
▸ PDE4A P27815 1/20 0.36
▸ PDE4D Q08499 1/20 0.36
▸ ALOX5 P09917 1/20 0.36
▸ PTGS2 P35354 1/20 0.36
▸ NQO2 P16083 3/20 0.33
▸ POLB P06746 1/20 0.33
▸ HTR2A P28223 2/20 0.33
▸ JAK3 P52333 1/20 0.33
▸ MKNK1 Q9BUB5 1/20 0.33
▸ EGFR P00533 1/20 0.33
▸ KDR P35968 1/20 0.33
▸ PGK1 P00558 1/20 0.33
▸ HTR2C P28335 1/20 0.33
▸ TAAR1 Q96RJ0 1/20 0.33
▸ STING1 Q86WV6 1/20 0.32
▸ ESR1 P03372 1/20 0.32
▸ ESR2 Q92731 1/20 0.32
▸ ELANE P08246 1/20 0.32
▸ AMY1A P0DUB6 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30170771 0.82 ELANE (0.41) ALOX5NQO2HTR2AEGFRKDR
SCHEMBL24791028 0.79 PDE4A (0.49) AXLPDE4APDE4DALOX5PTGS2
SCHEMBL15819106 0.74 NTSR1 (0.49) PDE4APDE4DPGK1ELANE
SCHEMBL24792079 0.73 L3MBTL1 (0.36) AXLJAK3MKNK1STING1ESR1
SCHEMBL5040481 0.73 ESR1 (0.40) AXLPDE4APDE4DALOX5PTGS2
SCHEMBL15819418 0.72 NTSR1 (0.51) PDE4APDE4DPGK1ELANE
SCHEMBL24792437 0.71 PDE4D (0.45) PDE4APDE4DKDR
SCHEMBL20355452 0.71 JAK3 (0.51) JAK3MKNK1EGFRKDR
SCHEMBL15819572 0.71 HTT (0.41) PDE4APDE4DPOLBEGFRKDR
SCHEMBL15818956 0.71 NTSR1 (0.52) PDE4APDE4DPOLBELANE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022262691-A1 HETEROCYCLIC COMPOUNDS AS SOS1 INHIBITORS BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) 2022-12-22 — — WO disclosed
Send feedback